Hsbc Holdings PLC Alaunos Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$1.44 - $2.73 $18,558 - $35,184	-12,888 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.63 - $3.67 $33,895 - $47,298	12,888 New	12,888 $34,000
Q1 2021 May 14, 2021	SELL	$2.82 - $5.6 $55,534 - $110,280	-19,693 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.09 - $3.09 $41,158 - $60,851	19,693 New	19,693 $49,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $3.43 $27,917 - $40,065	-11,681 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.2 - $3.71 $2,855 - $4,815	-1,298 Reduced 10.0%	11,681 $38,000
Q1 2020 May 15, 2020	BUY	$1.9 - $4.98 $24,660 - $64,635	12,979 New	12,979 $31,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.